Literature DB >> 35317613

Clinical Importance of Superior Sensitivity of the Aptima TMA-Based Assays for Mycoplasma genitalium Detection.

Kirsten Salado-Rasmussen1,2, Jacob Tolstrup1, Farnam Barati Sedeh1, Helle Kiellberg Larsen1, Magnus Unemo3, Jørgen Skov Jensen2.   

Abstract

Mycoplasma genitalium (MG) is a common cause of nongonococcal cervicitis and urethritis. We investigated the demographic and clinical characteristics of patients tested in Denmark with the Conformité Européenne (CE)/in vitro diagnostics (IVD) Aptima Mycoplasma genitalium assay (CE/IVD AMG; Hologic) and examined the clinical significance of the higher sensitivity of the TMA-based MG assays. From March to June 2016, urogenital and extragenital specimens from consecutive attendees at a sexually transmitted infection clinic in Copenhagen, Denmark were tested with the CE/IVD AMG assay (TMA-based), the research-use-only MG Alt TMA-1 assay (Hologic), a laboratory-developed TaqMan mgpB quantitative real-time PCR (qPCR), and the Aptima Combo 2 (CT/NG; Hologic). Demographic characteristics and clinical symptoms were collected from the patient records. There were 1,245 patients included in the study. The MG prevalence among female subjects was 9.4%, and the MG prevalence among male subjects was 8.7%. Compared to the TMA-based assays, the sensitivity of the PCR-based MG assay was 64.52%, and 55 specimens from 48 individuals were missed in the mgpB qPCR. Of these, 26 individuals (54.2%) were symptomatic, whereas, among 64 individuals with concordant results, 30 individuals (46.9%) were symptomatic; no statistically significant difference was found between the groups (P = 0.567). The improved sensitivity of the TMA-based assays resulted in diagnoses of more patients with clinically relevant symptoms for which antibiotic treatment is indicated. However, approximately half of the MG-infected patients reported no symptoms, and future research is needed to investigate the pros and cons of diagnosing and treating MG in asymptomatic subjects.

Entities:  

Keywords:  Aptima; Mycoplasma genitalium

Mesh:

Substances:

Year:  2022        PMID: 35317613      PMCID: PMC9020335          DOI: 10.1128/jcm.02369-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  23 in total

Review 1.  Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis.

Authors:  Rebecca Lis; Ali Rowhani-Rahbar; Lisa E Manhart
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

Review 2.  Mycoplasma genitalium: from Chrysalis to multicolored butterfly.

Authors:  David Taylor-Robinson; Jørgen Skov Jensen
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Signs and symptoms of urethritis and cervicitis among women with or without Mycoplasma genitalium or Chlamydia trachomatis infection.

Authors:  L Falk; H Fredlund; J S Jensen
Journal:  Sex Transm Infect       Date:  2005-02       Impact factor: 3.519

4.  Detection of several Mycoplasma species at various anatomical sites of homosexual men.

Authors:  D Taylor-Robinson; C B Gilroy; F E Keane
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-05-07       Impact factor: 3.267

5.  2016 European guideline on the management of non-gonococcal urethritis.

Authors:  Patrick J Horner; Karla Blee; Lars Falk; Willem van der Meijden; Harald Moi
Journal:  Int J STD AIDS       Date:  2016-05-04       Impact factor: 1.359

6.  Is Mycoplasma genitalium in women the "New Chlamydia?" A community-based prospective cohort study.

Authors:  Pippa Oakeshott; Adamma Aghaizu; Phillip Hay; Fiona Reid; Sally Kerry; Helen Atherton; Ian Simms; David Taylor-Robinson; Birthe Dohn; Jorgen S Jensen
Journal:  Clin Infect Dis       Date:  2010-10-13       Impact factor: 9.079

7.  Sex-associated Risk Factors for Co-infection with Chlamydia trachomatis and Neisseria gonorrhoea among Patients Presenting to a Sexually Transmitted Infection Clinic.

Authors:  Farnam Barati Sedeh; Simon F Thomsen; Helle K Larsen; Henrik Westh; Kirsten Salado-Rasmussen
Journal:  Acta Derm Venereol       Date:  2021-01-04       Impact factor: 3.875

8.  Molecular Testing for Mycoplasma genitalium in the United States: Results from the AMES Prospective Multicenter Clinical Study.

Authors:  Charlotte A Gaydos; Lisa E Manhart; Stephanie N Taylor; Rebecca A Lillis; Edward W Hook; Jeffrey D Klausner; Carmelle V Remillard; Melissa Love; Byron McKinney; Damon K Getman
Journal:  J Clin Microbiol       Date:  2019-10-23       Impact factor: 5.948

9.  Prevalence of human papillomavirus infection in the oropharynx and urine among sexually active men: a comparative study of infection by papillomavirus and other organisms, including Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma spp., and Ureaplasma spp.

Authors:  Kazufumi Nakashima; Kazuyoshi Shigehara; Shohei Kawaguchi; Akira Wakatsuki; Yoshitomo Kobori; Kazuyoshi Nakashima; Yasunori Ishii; Masayoshi Shimamura; Toshiyuki Sasagawa; Yasuhide Kitagawa; Atsushi Mizokami; Mikio Namiki
Journal:  BMC Infect Dis       Date:  2014-01-27       Impact factor: 3.090

10.  Epidemiology of Mycoplasma genitalium in British men and women aged 16–44 years: evidence from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Authors:  Pam Sonnenberg; Catherine A Ison; Soazig Clifton; Nigel Field; Clare Tanton; Kate Soldan; Simon Beddows; Sarah Alexander; Rumena Khanom; Pamela Saunders; Andrew J Copas; Kaye Wellings; Catherine H Mercer; Anne M Johnson
Journal:  Int J Epidemiol       Date:  2015-12       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.